Log in

NASDAQ:BCPCBalchem Stock Price, Forecast & News

$103.46
+1.50 (+1.47 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$100.83
Now: $103.46
$103.65
50-Day Range
$87.34
MA: $95.51
$101.96
52-Week Range
$78.30
Now: $103.46
$113.93
Volume90,124 shs
Average Volume129,235 shs
Market Capitalization$3.35 billion
P/E Ratio40.89
Dividend Yield0.50%
Beta0.62
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include creamer and chocolate systems, dairy replacers, powdered fats, nutritional beverage bases, beverages, juice and dairy bases, ice cream bases and variegates, cereals, grain based snacks, and cereal based ingredients. This segment also offers microencapsulation solutions; and human grade choline nutrients and mineral amino acid chelated products for wellness applications. Its Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The company's Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. It also sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company's Industrial Products segment provides choline chloride derivatives for hydraulic fracturing of shale natural gas wells; and methylamines, which are building blocks for the manufacture of choline products, as well as used in industrial applications. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was founded in 1967 and is headquartered in New Hampton, New York.
Read More
Balchem logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.7Dividend Strength: 2.5Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Chemicals & allied products
Sub-IndustrySpecialty Chemicals
Current SymbolNASDAQ:BCPC
CUSIP05766520
CIK9326
Phone845-326-5600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$643.71 million
Cash Flow$4.65 per share
Book Value$23.12 per share

Profitability

Net Income$79.67 million

Miscellaneous

Employees1,424
Market Cap$3.35 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$103.46
+1.50 (+1.47 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BCPC News and Ratings via Email

Sign-up to receive the latest news and ratings for BCPC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Balchem (NASDAQ:BCPC) Frequently Asked Questions

How has Balchem's stock been impacted by COVID-19 (Coronavirus)?

Balchem's stock was trading at $89.29 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BCPC stock has increased by 15.9% and is now trading at $103.46.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Balchem?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Balchem in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Balchem
.

When is Balchem's next earnings date?

Balchem is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Balchem
.

How were Balchem's earnings last quarter?

Balchem Co. (NASDAQ:BCPC) posted its quarterly earnings data on Friday, July, 31st. The basic materials company reported $0.85 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.55 by $0.30. The basic materials company earned $173.36 million during the quarter, compared to the consensus estimate of $161.35 million. Balchem had a return on equity of 14.32% and a net margin of 12.18%. The business's revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter last year, the business earned $0.77 EPS.
View Balchem's earnings history
.

How often does Balchem pay dividends? What is the dividend yield for Balchem?

Balchem announced an annual dividend on Wednesday, December 18th. Shareholders of record on Monday, December 30th will be paid a dividend of $0.52 per share on Friday, January 17th. This represents a yield of 0.51%. The ex-dividend date is Friday, December 27th. This is an increase from Balchem's previous annual dividend of $0.47.
View Balchem's dividend history
.

What price target have analysts set for BCPC?

2 analysts have issued 1 year target prices for Balchem's stock. Their forecasts range from $100.00 to $126.00. On average, they expect Balchem's share price to reach $113.00 in the next year. This suggests a possible upside of 9.2% from the stock's current price.
View analysts' price targets for Balchem
.

Has Balchem been receiving favorable news coverage?

News coverage about BCPC stock has been trending negative this week, according to InfoTrie. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Balchem earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned news articles about the basic materials company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about Balchem
.

Are investors shorting Balchem?

Balchem saw a decrease in short interest in July. As of July 31st, there was short interest totaling 433,300 shares, a decrease of 12.4% from the July 15th total of 494,500 shares. Based on an average trading volume of 167,300 shares, the days-to-cover ratio is presently 2.6 days. Approximately 1.4% of the shares of the company are sold short.
View Balchem's Short Interest
.

Who are some of Balchem's key competitors?

What other stocks do shareholders of Balchem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Balchem investors own include Gilead Sciences (GILD), AbbVie (ABBV), CVS Health (CVS), Ecolab (ECL), Adobe (ADBE), Mastercard (MA), Altria Group (MO), NVIDIA (NVDA), Pfizer (PFE) and Starbucks (SBUX).

Who are Balchem's key executives?

Balchem's management team includes the following people:
  • Mr. Theodore L. Harris, Chairman and Chief Exec. Officer (Age 54)
  • Mr. William A. Backus CPA, Chief Accounting Officer (Age 53)
  • Mr. Mark A. Stach, Gen. Counsel & Corp. Sec.
  • Mr. David F. Ludwig, VP & Gen. Mang. of Industrial Products (Age 61)
  • Mr. Carl Martin Bengtsson, Chief Financial Officer

What is Balchem's stock symbol?

Balchem trades on the NASDAQ under the ticker symbol "BCPC."

Who are Balchem's major shareholders?

Balchem's stock is owned by many different institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (2.75%), GW&K Investment Management LLC (1.12%), New York State Common Retirement Fund (0.96%), Principal Financial Group Inc. (0.76%), Tributary Capital Management LLC (0.68%) and Assenagon Asset Management S.A. (0.40%). Company insiders that own Balchem stock include Daniel E Knutson, David F Ludwig and Scott C Mason.
View institutional ownership trends for Balchem
.

Which major investors are selling Balchem stock?

BCPC stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, ProShare Advisors LLC, Moody Aldrich Partners LLC, Principal Financial Group Inc., PNC Financial Services Group Inc., SG Americas Securities LLC, Brinker Capital Inc., and Bath Savings Trust Co.
View insider buying and selling activity for Balchem
.

Which major investors are buying Balchem stock?

BCPC stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Conestoga Capital Advisors LLC, GW&K Investment Management LLC, First Trust Advisors LP, Tributary Capital Management LLC, Raymond James & Associates, Swiss National Bank, and Quantitative Systematic Strategies LLC. Company insiders that have bought Balchem stock in the last two years include Daniel E Knutson, and Scott C Mason.
View insider buying and selling activity for Balchem
.

How do I buy shares of Balchem?

Shares of BCPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Balchem's stock price today?

One share of BCPC stock can currently be purchased for approximately $103.46.

How big of a company is Balchem?

Balchem has a market capitalization of $3.35 billion and generates $643.71 million in revenue each year. The basic materials company earns $79.67 million in net income (profit) each year or $3.19 on an earnings per share basis. Balchem employs 1,424 workers across the globe.

What is Balchem's official website?

The official website for Balchem is www.balchem.com.

How can I contact Balchem?

Balchem's mailing address is 52 Sunrise Park Road, NEW HAMPTON NY, 10958. The basic materials company can be reached via phone at 845-326-5600 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.